Beta-blocker use and the development of depression.
van Melle
Joost P
JP
de Jonge
Peter
P
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D001578:Benzopyrans / Q000009:adverse effects* / Q000627:therapeutic use; D003863:Depression / Q000139:chemically induced* / Q000453:epidemiology; D003866:Depressive Disorder / Q000139:chemically induced / Q000453:epidemiology; D004305:Dose-Response Relationship, Drug; D004983:Ethanolamines / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy; D015994:Incidence; D008297:Male; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy; D000068577:Nebivolol; D018570:Risk Assessment
D000319:Adrenergic beta-Antagonists; D001578:Benzopyrans; D004983:Ethanolamines; D000068577:Nebivolol